HIV vaccine

Details HIV vaccine HIV vaccine

2006-06-27

2006-06-27

Parkin, Jeffrey S. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C424S208100, C435S236000

Reexamination Certificate

active

07067134

ABSTRACT:
A novel HIV vaccine is provided. In particular, the vaccine comprises an avirulent and non-cytolytic recombinant HIV wherein the NSS of the virus' envelope glycoprotein is replaced with a non-cytolytic signal sequence and nef gene of the virus is deleted which renders the virus avirulent.

REFERENCES:
patent: WO 9417825 (1994-08-01), None
Haynes, B. F., et al., 1996, “Update on the issues of HIV vaccine development”, Ann. Med. 28:39-41.
Haynes, B. F., 1996, “HIV vaccines: where are we and where are we going?”, Lancet 348:933-37.
Burton, D. R., and J. P. Moore, 1998, “Why do we not have an HIV vaccine and how can we make one?”, Nat. Med. Vac. Suppl. 4(5):495-98.
Letvin, N. L., 1998, “Progess in the development of an HIV-1 vaccine”, Science 280:1875-1880.
Lee, T.-H., 1997, “Acquired immunodeficiency disease vaccines: design and development”, in AIDS: Biology, Diagnosis, Treatment, and Prevention, fourth edition, DeVita, Jr., V. T., et al., eds., Lippincott-Raven Publishers, pp. 605-616.
Stevenson, M., et al., 1988, “Envelope glycoprotein of HIV induces interference and cytolysis resistance in CD4+ cells: mechanism for persistence in AIDS”, Cell 53(3):483-496 (abstract provided).
Siliciano, R. F., et al., 1988, “Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: effect of HIV sequence variation and mechanism for CD4+ cell depletion”, Cell 54(4):561-575 (abstract provided).
Weinhold, K., et al., 1989, “HIV-1 gp120-mediated immune suppression and lymphocyte destruction in the absence of viral infection”, J. Immunol. 142(9):3091-3097 (abstract provided).
Jassoy, C., et al., 1993, “Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes . . . ”, J. Virol. 67(5):2844-2852.
Banda, N. K., et al., 1992, “Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis”, J. Exp. Med. 176(4):1099-1106 (abstract provided).
Laurent-Crawford, A. G., et al., 1993, “Membrane expression of HIV envelope glycoproteins triggers apoptosis in CD4 cells”, AIDS Res. Human Retrovir. 9(8):761-773 (abstract provided).
Li, Y., et al., 1994, “Control of expression, glycosylation, and secretion of HIV-1 gp120 by homologous and heterologous signa sequences”, Virol. 204:266-278.
Li, Y., et al., 1996, “Effects of inefficient cleavage of the signal sequence of HIV-1 gp120 on its asociation with calnexin, folding and intracellular transport”, Proc. Natl. Acad. Sci. USA 93:9606-9611.
Daniel, M. D., et al., 1992, “Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene”, Science 258(5090):1938-41 (abstract provided).
Chakrabarti et al., Proceedings of the National Academy of Sciences of USA, vol. 93, No. 18, p. 9810-9815 (1996).
Li et al., Proceedings of the National Academy of Sciences of USA, vol. 93, No. 18, p. 9606-9611 (1996).
Li et al., Virology, vol. 204, No. 1, p. 266-278 (1994).

Affiliated with

Also associated with

Rating

HIV vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HIV vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3632468